Michael G McDonell1, Jenny R Nepom2, Emily Leickly2, Astrid Suchy-Dicey2, Kait Hirchak3, Abigail Echo-Hawk2, Stephen M Schwartz4, Darren Calhoun5, Dennis Donovan6, John Roll7, Richard Ries6, Dedra Buchwald1. 1. Partnerships for Native Health, Department of Epidemiology, University of Washington, 1100 Olive Way, Suite 1200, Box 357236, Seattle, WA 98101, USA; Elson S Floyd College of Medicine, Washington State University, USA. 2. Partnerships for Native Health, Department of Epidemiology, University of Washington, 1100 Olive Way, Suite 1200, Box 357236, Seattle, WA 98101, USA. 3. Department of Health Policy and Administration, Washington State University, Spokane, WA 99210-1495, USA. 4. Partnerships for Native Health, Department of Epidemiology, University of Washington, 1100 Olive Way, Suite 1200, Box 357236, Seattle, WA 98101, USA; Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109-1024, USA. 5. Med Star Health Research Institute, 1616 E. Indian School Rd., Phoenix, AZ 85016, USA. 6. Department of Psychiatry and Behavioral Sciences, University of Washington, 325 Ninth Ave, Box 359911, Seattle, WA 98195, USA. 7. Washington State University, Spokane, WA 99210-1495, USA.
Abstract
BACKGROUND: Disproportionately high rates of alcohol use disorders are present in many American Indian/Alaska Native (AI/AN) communities, yet little information exists regarding the effectiveness of alcohol treatments in AI/AN populations. Contingency management is an intervention for illicit drug use in which tangible reinforcers (rewards) are provided when patients demonstrate abstinence as assessed by urine drug tests. Contingency management has not been widely studied as an intervention for alcohol problems because until recently, no alcohol biomarker has been available to adequately verify abstinence. AIMS: The HONOR Study is designed to determine whether a culturally-tailored contingency management intervention is an effective intervention for AI/AN adults who suffer from alcohol use disorders. METHODS:Participants include 400 AI/AN alcohol-dependent adults residing in one rural reservation, one urban community, as well as a third site to be decided, in the Western U.S. Participants complete a 4-week lead-in phase prior to randomization, then 12 weeks of either acontingency management intervention for alcohol abstinence, or a control condition where participants receive reinforcers for attending study visits regardless of alcohol use. Participants are then followed for 3-more months post-intervention. The primary study outcome is urinary ethyl glucuronide-confirmed alcohol abstinence; secondary outcomes include self-reported alcohol and drug use, HIV risk behaviors, and self-reported cigarette smoking. DISCUSSION: This will be the largest randomized, controlled trial of any alcohol for AI/ANs and the largest contingency management study targeting alcohol use disorders, thus providing important information to AI/AN communities and the alcohol treatment field in general.
RCT Entities:
BACKGROUND: Disproportionately high rates of alcohol use disorders are present in many American Indian/Alaska Native (AI/AN) communities, yet little information exists regarding the effectiveness of alcohol treatments in AI/AN populations. Contingency management is an intervention for illicit drug use in which tangible reinforcers (rewards) are provided when patients demonstrate abstinence as assessed by urine drug tests. Contingency management has not been widely studied as an intervention for alcohol problems because until recently, no alcohol biomarker has been available to adequately verify abstinence. AIMS: The HONOR Study is designed to determine whether a culturally-tailored contingency management intervention is an effective intervention for AI/AN adults who suffer from alcohol use disorders. METHODS:Participants include 400 AI/AN alcohol-dependent adults residing in one rural reservation, one urban community, as well as a third site to be decided, in the Western U.S. Participants complete a 4-week lead-in phase prior to randomization, then 12 weeks of either a contingency management intervention for alcohol abstinence, or a control condition where participants receive reinforcers for attending study visits regardless of alcohol use. Participants are then followed for 3-more months post-intervention. The primary study outcome is urinary ethyl glucuronide-confirmed alcohol abstinence; secondary outcomes include self-reported alcohol and drug use, HIV risk behaviors, and self-reported cigarette smoking. DISCUSSION: This will be the largest randomized, controlled trial of any alcohol for AI/ANs and the largest contingency management study targeting alcohol use disorders, thus providing important information to AI/AN communities and the alcohol treatment field in general.
Authors: John M Roll; Nancy M Petry; Maxine L Stitzer; Mary L Brecht; Jessica M Peirce; Michael J McCann; Jack Blaine; Marilyn MacDonald; Joan DiMaria; Leroy Lucero; Scott Kellogg Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: W Gill Woodall; Harold D Delaney; Stephen J Kunitz; Verner S Westerberg; Hongwei Zhao Journal: Alcohol Clin Exp Res Date: 2007-03-31 Impact factor: 3.455
Authors: Richard A Rawson; Michael J McCann; Frank Flammino; Steven Shoptaw; Karen Miotto; Chris Reiber; Walter Ling Journal: Addiction Date: 2006-02 Impact factor: 6.526
Authors: Sara A Quandt; Christopher N Graham; Ronny A Bell; Beverly M Snively; Shannon L Golden; Jeanette M Stafford; Thomas A Arcury Journal: Ethn Dis Date: 2007 Impact factor: 1.847
Authors: Jessica M Peirce; Nancy M Petry; Maxine L Stitzer; Jack Blaine; Scott Kellogg; Frank Satterfield; Marion Schwartz; Joe Krasnansky; Eileen Pencer; Lolita Silva-Vazquez; Kimberly C Kirby; Charlotte Royer-Malvestuto; John M Roll; Allan Cohen; Marc L Copersino; Ken Kolodner; Rui Li Journal: Arch Gen Psychiatry Date: 2006-02
Authors: Ekaterina Burduli; Jordan Skalisky; Katherine Hirchak; Michael F Orr; Albert Foote; Alexandria Granbois; Richard Ries; John M Roll; Dedra Buchwald; Michael G McDonell; Sterling M McPherson Journal: Clin Trials Date: 2018-08-29 Impact factor: 2.486
Authors: Katherine A Hirchak; Emily Leickly; Jalene Herron; Jennifer Shaw; Jordan Skalisky; Lisa G Dirks; Jaedon P Avey; Sterling McPherson; Jenny Nepom; Dennis Donovan; Dedra Buchwald; Michael G McDonell Journal: J Subst Abuse Treat Date: 2018-05-03
Authors: Thaius Boyd; Jordan Stipek; Alex Kraft; Judge Muskrat; Kevin A Hallgren; Clinton Alexander; Brenna Greenfield Journal: Drug Alcohol Depend Date: 2021-03-18 Impact factor: 4.492
Authors: Katherine A Hirchak; Abram J Lyons; Jalene L Herron; Gordon Kordas; Jennifer L Shaw; Kelley Jansen; Jaedon P Avey; Sterling M McPherson; Dennis Donovan; John Roll; Dedra Buchwald; Richard Ries; Michael G McDonell Journal: J Subst Abuse Treat Date: 2021-12-11
Authors: Kate M Lillie; Kelley J Jansen; Lisa G Dirks; Abram J Lyons; Karl C Alcover; Jaedon P Avey; Katherine Hirchak; Jalene Herron; Dedra Buchwald; Dennis M Donovan; Michael G McDonell; Jennifer L Shaw Journal: J Addict Med Date: 2020 Sep/Oct Impact factor: 4.647
Authors: Olamide Ojo-Fati; Anne M Joseph; Jed Ig-Izevbekhai; Janet L Thomas; Susan A Everson-Rose; Rebekah Pratt; Nancy Raymond; Ned L Cooney; Xianghua Luo; Kolawole S Okuyemi Journal: Trials Date: 2017-07-05 Impact factor: 2.279
Authors: Sterling M McPherson; Ekaterina Burduli; Crystal Lederhos Smith; Jalene Herron; Oladunni Oluwoye; Katherine Hirchak; Michael F Orr; Michael G McDonell; John M Roll Journal: Subst Abuse Rehabil Date: 2018-08-13